Introduction
Vaccination against influenza A infection has undoubtedly saved millions of lives, but zoonotic influenza represents a continuous source of potentially new infectious virus strains, either by mutation to promote human infections, or by genetic shift through reassortment with a human seasonal influenza.
Since 1997, H5N1 has emerged as a potentially pandemic virus from human contact with infectious birds [1] , with an alarmingly high fatality rate of ~53% [2] . Unfortunately the H5N1 virus continues to generate a high rate of mutation, and many new clades of virus [3] [4] [5] . This is of special concern, because 1) the strain banked against a possible pandemic may not be immunologically relevant [6] , 2) the poor efficacy of the current vaccine will require two immunizations (with adjuvant) to achieve homologous or heterologous immunity in vaccinated individuals [7, 8] , or 3) that it will take months to scale up embryonated egg-based vaccine production, which may be too slow to facilitate mass immunization.
Significant progress has been made to rapidly produce H5N1 vaccines by expression of the Hemagglutinin (HA) protein as the vaccine agent. HA protein is the main stimulus of virus neutralization, and can be made independently of the whole virus. Production is much safer, simpler and faster [9] , and H5 HA immunization generates protective immunity in mice [10] , ferrets [11, 12] and in humans [13] [14] [15] . But, H5 HA protein is weakly immunogenic, and requires boosting and/or adjuvant use for inducing effective immunity, so immune potency is still an issue. We have optimized HA formulation by chemically associating H5 HA protein to the surface of, Tobacco Mosaic Virus (TMV), a noninfectious plant virus. TMV is an attractive virus carrier, because it has the optimal size to promote immune cell uptake [16, 17] , can be made at Kg scale in planta with a minimum of processing steps, and is not a mammalian pathogen [18] . We have developed a TMV coat protein variant that expresses a surface exposed lysine [19] that allows for high density association of HA protein to the virus surface, using a one step conjugation chemistry [20] . In this study, we have greatly improved the low immunogenicity of H5 HA subunit vaccination by TMV-H5 conjugation, with equivalent immune activation potency as an MF-59-like squalene adjuvant. This could be an important advance in development of dose-sparing protective HA vaccines that are based on subunit antigen delivery by virus co-formulation.
Materials and methods

Conjugation and Vaccine preparation
Chemical conjugation of an H5 HA1 Fc fusion protein (10003-V06H1, Sino Biological Inc.,) to the surface of lysine modified TMV virus [19] , was done as previously described [20] . Conjugation reactions were considered complete when no free HA protein was visible by SDS-PAGE. After conjugation, reactive agents were removed by overnight dialysis against PBS in Slide-a-Lyzer cartridge (Thermo-Scientific), and the protein quantity was determined by the Bicinchoninic Acid Assay (BCA;BioRad), and HA content was quantified by Enzyme Linked Immunosorbent Assay (ELISA), to normalize the vaccine dose.
Vaccination and immune response evaluation in mice
BALB/c mice (Charles River, CA) were housed at Touro University according to guidelines established in the Care and Use of Animals and according to IACUC approved protocols. Mice were given a 100 -200 µl subcutaneous (s.c.) injection of 7.5 μg HA protein (unconjugated), or the equivalent HA as a 15 μg conjugate, with or without a squalene based oil-in-water emulsion adjuvant AddaVax™ (1:1 ratio; InvivoGen). Inactivated H5N1 virus was used as a positive control, and pre-immune serum was used to determine baseline sera titers. Vaccines were administered on day one and day 30, and sera was collected by tail vein bleed on days 14 and 28 days post vaccine 1 (pV1) or day 44, 14 days post vaccine 2 (pV2) for ELISA analysis.
ELISA was used to determine serum IgG titers as previously described [21] . Anti-H5 titers reported in ng/ml were determined from a standard curve generated by a 3-fold serial dilution of a 10 ng/ml mouse anti-HA monoclonal antibody (DPJY01, BEI #NR-19869). Hemagglutinin Inhibition (HAI) titers of the sera were then determined by the standard microtitration method [22] , with serial 2-fold dilution of serum mixed with 0.5% turkey Red Blood Cells (RBCs; Innovative Research, Inc.) in sterile phosphate buffered saline (PBS;Gibco).
H5N1 virus challenge
H5N1 virus challenge studies were conducted under animal Bio-safety level 3 (ABSL3) conditions and according to St. Jude Children's Research Hospital approved institutional procedures and protocols. Ten week old BALB/c mice were vaccinated once, using 15 µg H5 protein equivalent, or two times 14 days apart with 7.5 µg H5 protein equivalent, with or without squalene based adjuvant. At day 26, serum was collected for ELISA and HAI analysis, and on day 28, mice were challenged intranasally with 10xLD50 of highly pathogenic avian A/Vietnam/1203/04, diluted in 50 µL of PBS, as previously described [23] . Mice were monitored daily for >25% weight loss, neurologic signs, or motor dysfunction, and were euthanized according to IACUC approved procedures.
Results and discussion
TMV-H5 HA conjugation and pilot immunization
As shown in Figure 1 , we used EDC/NHS (1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide) conjugation of H5 HA (H5 HA1-Fc protein; Sino Biological Inc.,) to a lysine modified TMV as previously described [20] . After 30 minutes, both TMV (triangle) and HA (circle) are reduced, and a high molecular weight aggregate (TMV-H5) accumulates in the gel above 250 kDa, and in the stack after 8-16% SDS-PAGE separation (arrow). A TMV dimer and tetramer are also visible (asterisks).
To assess immune response titers, 7.5 µg of HA equivalent protein as TMV-H5 conjugate was used to immunize mice (n=3), with or without a squalene based oil-in-water adjuvant (Sq; InvivoGen). Inactivated H5N1 virus was also used as a positive control, and H5 protein given +/-Sq was used to control for HA immune reactivity without TMV. Mice were tested for anti-HA IgG 14 and 28 days after a single dose, and at day 44, 14 days after a boost on day 30. As shown in Figure 2A , all immunized mice had measureable anti-H5 specific IgG titers after a single dose of TMV-H5, when compared to an anti-H5 monoclonal antibody standard (DPJY01, BEI #NR-19869). Only TMV-H5 with Sq had significantly better immune titers (* p < 0.05) than any of the other vaccine groups, suggesting synergy in H5 immune potentiation between TMV and adjuvant. Notably, TMV-H5 had statistically similar immune titers compared to H5 HA . Virus at 4 fold greater than the minimum agglutinating titer was then pretreated with serial dilutions of RDE-treated serum from study sera. After 1 hour, 0.05% turkey red blood cells were added, and HAI titer was measured as the inverse of the minimum dilution blocking the formation of RBC agglutination (RBC buttons). TMV vaccination gave titers equivalent to pre-immune sera (not shown).
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protein given with squalene (NS; not significantly different), indicating that TMV provides adjuvant activity equivalent to that of squalene emulsions [20] . After two weeks ( Figure 2B ), the immune response to TMV-H5 Sq nearly doubled (mean 6.3 vs 11.1), suggesting that TMV-HA vaccines may also provide a depot effect. Two weeks after a second immunization ( Figure  2C ), TMV-H5 Sq boosted mice had a log increase in IgG titer (mean 11.1 vs 140.0) which was significantly better than other vaccine groups (p < 0.001), and all other immune responses were statistically similar to each other (NS).
Although IgG titers were low for both H5N1 virus and H5 HA Sq after two immunizations, significant HAI titers (> 40) were measured for all vaccine groups except HA protein given without adjuvant (* p < 0.05; Figure 2D ), indicating both quantitative and qualitative boosting of TMV-HA conjugate vaccines.
Immunization and protection from H5N1 viral challenge
As shown in Figure 3A , mice were immunized following a similar strategy in the pilot study. Mice (n=10) were vaccinated with either one dose (15 µg total HA protein) on day 1, or two doses on days 1 and 14 (7.5 µg each dose, 15 µg total HA protein), with or without oil-in-water squalene (Sq) adjuvant as indicated. HA only was not tested in this study due to lack of IgG and HAI responses in the pilot study. Sera were collected on day 28, and mice were challenged on day 30 by intranasal administration of 10xLD50 of A/Vietnam/1203/04. Mice were monitored for symptoms of infection (weight loss, neurological or behavioral changes), and euthanized according to IACUC protocols. As shown in Figure 3B , IgG immune response titers were slightly different than the pilot, especially in regards to inactivated H5N1 virus responses, which were much higher than in the pilot, possibly due to differences in preparations and estimates of HA content. Another difference, was the low IgG induced by TMV-HA, after either one or two vaccines. However, after one dose TMV-HA+Sq induced significantly higher IgG titers than HA+Sq (p < 0.05) and was not different than inactivated virus immunization. After two doses, TMV-HA+Sq, HA+Sq and H5N1 virus immunization induced similar levels of IgG. In contrast, HAI titers ( Figure 3C ) for TMV-HA were significantly better after two doses than HA+Sq, with or without squalene adjuvant addition. After a single dose, HAI titer was also significantly better in the TMV-HA+Sq than HA+Sq vaccine group (p < 0.05), but was not above background (< 40) in the TMV-HA group.
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At day 30, mice were challenged with a lethal dose of A/ Vietnam/1203/04, and monitored for weight changes and survival. After one immunization, TMV-HA+Sq generated equivalent protection to inactivated H5N1 virus vaccination (100% of mice) both in terms of weight loss ( Figure 4A ) and survival ( Figure 4B) . Surprisingly, despite low IgG and low HAI for TMV-HA after one dose (no adjuvant), we measured 40% survival, equivalent to HA+Sq ( Figure 4B ), indicating that TMV provides immune activation activity similar or equal to that of a squalene-based MF-59-like adjuvant. After two immunizations, all vaccine groups had statistically similar survival (90-100%; p > 0.9), irrespective of adjuvant use, and compared to the PBS control (p < 0.01).
Ongoing studies to further improve TMV-HA formulations include intranasal administration, to improve mucosal immunity, multivalent combinations of various TMV-HAs, and additional adjuvant co-formulations. Preliminary data suggest higher mean titers of anti-H5 IgG are achieved with TMV-H5 intranasal dosing, but HAI, microneutralization analysis, cross protection, and challenge studies will be needed to confirm relevance to protection, similar to other studies using HA virus-like particles [24] , nanoparticles [25] or virus vaccines [26] .
